FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nina Isoherranen

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Drug Interactions

Concepts & Ideas

Living Beings

Disorders

Seizures

Co-author Network

Publications

TOP 3
Alice Ban Ke; Srikanth C Nallani; Amin Rostami-Hodjegan; Nina Isoherranen; Ping Zhao; Jashvant D Unadkat
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.
J J Nya-Ngatchou; S T Page; T J Walsh; S L M Arnold; Nina Isoherranen; Charles H Muller; J K Amory
Intratesticular 13-cis retinoic acid is lower in men with abnormal semen analyses: a pilot study.
Nina Isoherranen; Kenneth E Thummel
Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nina Isoherranen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alice Ban Ke; Srikanth C Nallani; Amin Rostami-Hodjegan; Nina Isoherranen; Ping Zhao; Jashvant D Unadkat
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(4):801-13.
2013: J J Nya-Ngatchou; S T Page; T J Walsh; S L M Arnold; Nina Isoherranen; Charles H Muller; J K Amory
Intratesticular 13-cis retinoic acid is lower in men with abnormal semen analyses: a pilot study.
Andrology 2013;1(2):325-31.
2013: Nina Isoherranen; Kenneth E Thummel
Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?
Drug metabolism and disposition: the biological fate of chemicals 2013;41(2):256-62.
2013: Ariel R Topletz; Joanne Wang; John D Chapman; Edward J Kelly; Huong N Le; Nora Lee; Nina Isoherranen
Hepatic Cyp2d and Cyp26a1 mRNAs and activities are increased during mouse pregnancy.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(2):312-9.
2013: Leslie J Dickmann; Nina Isoherranen
Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(2):270-4.
2012: Jakob A Shimshoni; Ariel R Topletz; Sean A Blankert; James R Halpert; Wendel L Nelson; Arthur G Roberts; Michele Scian; Nina Isoherranen
Stereoselective formation and metabolism of 4-hydroxy-retinoic Acid enantiomers by cytochrome p450 enzymes.
The Journal of biological chemistry 2012;287(50):42223-32.
2012: Nina Isoherranen; Rene H Levy; Justin D Lutz; Sophie P Chung; Houda Hachad; Isabelle Ragueneau-Majlessi
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.
Chemical research in toxicology 2012;25(11):2285-300.
2012: Yasushi Fujioka; Kent L Kunze; Nina Isoherranen
Risk assessment of mechanism-based inactivation in drug-drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(9):1653-7.
2012: Justin D Lutz; Nina Isoherranen
In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.
Expert opinion on drug metabolism & toxicology 2012;8(4):449-66.
2012: Samuel L M Arnold; John K Amory; Thomas J Walsh; Nina Isoherranen
A sensitive and specific method for measurement of multiple retinoids in human serum with UHPLC-MS/MS.
Journal of lipid research 2012;53(3):587-98.
2012: Chi-Chi Peng; Wei Shi; Kent L Kunze; Jun O Liu; Justin D Lutz; Wendel L Nelson; Nina Isoherranen
Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(3):426-35.
2012: J Yang; W M Atkins; Nina Isoherranen; Mary F Paine; Kenneth E Thummel
Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.
Clinical pharmacology and therapeutics 2012;91(3):442-9.
2012: Ariel R Topletz; Alex Zelter; Justin D Lutz; Wendel L Nelson; Suzanne Tay; Jayne E Thatcher; Nina Isoherranen
Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases.
Biochemical pharmacology 2012;83(1):149-63.
2011: C-C Peng; I Templeton; Kenneth E Thummel; C Davis; Kent L Kunze; Nina Isoherranen
Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.
Clinical pharmacology and therapeutics 2011;89(6):888-95.
2011: Robert S Foti; Mathew Honaker; Abhinav Nath; Josh T Pearson; Brian Buttrick; Nina Isoherranen; William M Atkins
Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function.
Biochemistry 2011;50(13):2387-93.
2011: C K Yeung; René H Levy; Y Fujioka; Houda Hachad; Nina Isoherranen
Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.
Clinical pharmacology and therapeutics 2011;89(1):105-13.
2011: Alysa A Walker; Leslie J Dickmann; Nina Isoherranen
Pregnancy decreases rat CYP1A2 activity and expression.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(1):4-7.
2011: John K Amory; Charles H Muller; Jakob A Shimshoni; Nina Isoherranen; Jisun Paik; Jan S Moreb; David W Amory; Ryan Evanoff; Alex S Goldstein; Michael D Griswold
Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis.
Journal of andrology 2011;32(1):111-9.
2010: I Templeton; C-C Peng; Kenneth E Thummel; C Davis; Kent L Kunze; Nina Isoherranen
Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
Clinical pharmacology and therapeutics 2010;88(4):499-505.
2010: Jayne E Thatcher; Alex Zelter; Nina Isoherranen
The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid.
Biochemical pharmacology 2010;80(6):903-12.
2010: Justin D Lutz; Yasushi Fujioka; Nina Isoherranen
Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.
Expert opinion on drug metabolism & toxicology 2010;6(9):1095-109.
2010: Lin Zhou; Suresh B Naraharisetti; Li Liu; Honggang Wang; Yvonne S Lin; Nina Isoherranen; Jashvant D Unadkat; Mary F Hebert; Qingcheng Mao
Contributions of human cytochrome P450 enzymes to glyburide metabolism.
Biopharmaceutics & drug disposition 2010;31(4):228-42.
2010: Suzanne Tay; Leslie J Dickmann; Vaishali Dixit; Nina Isoherranen
A comparison of the roles of peroxisome proliferator-activated receptor and retinoic acid receptor on CYP26 regulation.
Molecular pharmacology 2010;77(2):218-27.
2010: Brooke M VandenBrink; Nina Isoherranen
The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
Current opinion in drug discovery & development 2010;13(1):66-77.
2009: Jayne E Thatcher; Nina Isoherranen
The role of CYP26 enzymes in retinoic acid clearance.
Expert opinion on drug metabolism & toxicology 2009;5(8):875-86.
2009: Nina Isoherranen; Houda Hachad; Catherine K Yeung; Rene H Levy
Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database.
Chemical research in toxicology 2009;22(2):294-8.
2008: Leslie J Dickmann; Suzanne Tay; Tauri D Senn; Huixia Zhang; Anthony Visone; Jashvant D Unadkat; Mary F Hebert; Nina Isoherranen
Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy.
Biochemical pharmacology 2008;75(8):1677-87.
2008: Takanori Hashizume; Yang Xu; Michael A Mohutsky; Jeffrey Alberts; Chad Hadden; Thomas F Kalhorn; Nina Isoherranen; Margaret C Shuhart; Kenneth E Thummel
Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation.
Biochemical pharmacology 2008;75(5):1240-50.
2008: Nina Isoherranen; Shana R Ludington; Raymond C Givens; Jatinder Lamba; Susan N Pusek; Elizabeth Dees; David K Blough; Kazunori Iwanaga; Roy L Hawke; Erin G Schuetz; Paul B Watkins; Kenneth E Thummel; Mary F Paine
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(1):146-54.
2008: I E Templeton; Kenneth E Thummel; Evan D Kharasch; Kent L Kunze; Christine Hoffer; Wendel L Nelson; Nina Isoherranen
Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
Clinical pharmacology and therapeutics 2008;83(1):77-85.
2007: Evan D Kharasch; Alysa Walker; Nina Isoherranen; Christine Hoffer; Pamela Sheffels; Kenneth E Thummel; Dale Whittington; D Ensign
Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Clinical pharmacology and therapeutics 2007;82(4):410-26.
2006: Josh T Pearson; John J Hill; Jennifer Swank; Nina Isoherranen; Kent L Kunze; William M Atkins
Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations.
Biochemistry 2006;45(20):6341-53.
2006: Yang Dai; Mary F Hebert; Nina Isoherranen; Connie L Davis; Christopher Marsh; Danny D Shen; Kenneth E Thummel
Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(5):836-47.
2006: Kent L Kunze; Wendel L Nelson; Evan D Kharasch; Kenneth E Thummel; Nina Isoherranen
Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(4):583-90.
2004: Weili Huang; Yvonne S Lin; Donavon J McConn; Justina C Calamia; Rheem A Totah; Nina Isoherranen; Mary Glodowski; Kenneth E Thummel
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(12):1434-45.
2004: Nina Isoherranen; Kent L Kunze; Kyle E Allen; Wendel L Nelson; Kenneth E Thummel
Role of itraconazole metabolites in CYP3A4 inhibition.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(10):1121-31.
2004: Nina Isoherranen; René H Levy; Boris Yagen; José H Woodhead; H White; Meir Bialer
Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites.
Epilepsy research 2004;58(1):1-12.
2003: Nina Isoherranen; Ofer Spiegelstein; Meir Bialer; Jing Zhang; Michelle Merriweather; Boris Yagen; Michael Roeder; Aleata A Triplett; Volker Schurig; Richard Finnell
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.
Epilepsia 2003;44(10):1280-8.
2003: Nina Isoherranen; H White; Brian D Klein; Michael Roeder; José H Woodhead; Volker Schurig; Boris Yagen; Meir Bialer
Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.
Pharmaceutical research 2003;20(8):1293-301.
2003: Nina Isoherranen; Boris Yagen; Ofer Spiegelstein; Richard Finnell; Michelle Merriweather; José H Woodhead; Bogdan Wlodarczyk; H White; Meir Bialer
Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice.
British journal of pharmacology 2003;139(4):755-64.
2003: Malka Britzi; Stefan Soback; Nina Isoherranen; René H Levy; Emilio Perucca; Dennis R Doose; Bruce E Maryanoff; Meir Bialer
Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay.
Therapeutic drug monitoring 2003;25(3):314-22.
2003: Nina Isoherranen; Boris Yagen; Ofer Spiegelstein; Amir Steinman; Richard Finnell; Meir Bialer
Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;788(1):125-36.
2003: Nina Isoherranen; Boris Yagen; Meir Bialer
New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
Current opinion in neurology 2003;16(2):203-11.
2003: Nina Isoherranen; Boris Yagen; José H Woodhead; Ofer Spiegelstein; Simcha Blotnik; Karen S Wilcox; Richard Finnell; Gregory D Bennett; H White; Meir Bialer
Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.
British journal of pharmacology 2003;138(4):602-13.
2002: Amir Steinman; Nina Isoherranen; O Ashoach; Stefan Soback
Pharmacokinetics of gentamicin C1, C1a and C2 in horses after single intravenous dose.
Equine veterinary journal 2002;34(6):615-8.
2002: Nina Isoherranen; H White; Richard Finnell; Boris Yagen; José H Woodhead; Gregory D Bennett; Karen S Wilcox; Matthew E Barton; Meir Bialer
Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: a new antiepileptic drug.
Epilepsia 2002;43(2):115-26.
2001: Nina Isoherranen; José H Woodhead; H White; Meir Bialer
Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug.
Epilepsia 2001;42(7):831-6.
2001: Nina Isoherranen; Boris Yagen; Stefan Soback; Michael Roeder; Volker Schurig; Meir Bialer
Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs.
Epilepsia 2001;42(7):825-30.
2000: Nina Isoherranen; Michael Roeder; Stefan Soback; Boris Yagen; Volker Schurig; Meir Bialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):325-32.
2000: Nina Isoherranen; Stefan Soback
Determination of gentamicins C(1), C(1a), and C(2) in plasma and urine by HPLC.
Clinical chemistry 2000;46(6 Pt 1):837-42.
2000: Nina Isoherranen; Eran Lavy; Stefan Soback
Pharmacokinetics of gentamicin C(1), C(1a), and C(2) in beagles after a single intravenous dose.
Antimicrobial agents and chemotherapy 2000;44(6):1443-7.
1999: Nina Isoherranen; Stefan Soback
Chromatographic methods for analysis of aminoglycoside antibiotics.
Journal of AOAC International 1999;82(5):1017-45.